Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway Free

Malignant gliomas express tumor-associated and tumor-specific antigens that should make these tumors detectable to the immune system (1). However, there is a distinct lack of immune-mediated tumor eradication in glioma patients, and most attempts at immunotherapy have met with little clinical success (2). Many factors work in concert to inhibit antiglioma immunity, including immunosuppressive cytokines such as interleukin (IL)-10, transforming growth factor (TGF)-β, and prostaglandin E₂ (PGE₂), the induction of regulatory T cells (Treg), and the downmodulation of costimulation molecules by antigen-presenting cells resulting in loss of T-cell effector function—all of which are operational in glioblastoma multiforme (GBM) patients (reviewed in ref. 3). Although central nervous system (CNS) tumors are recognized by the immune system, this is insufficient for their suppression or eradication. Primed CD8+ cytotoxic T cells gain CNS access (4); however, the lack of tumor eradication indicates that the T cells mediating adaptive immune responses are deficient in malignant glioma patients and are functionally impaired within the local tumor microenvironment (5–9).

Cancer-initiating cells are a heterogeneous population of undifferentiated cells with the capacity for self-renewal and a high proliferative potential. GBMs contain cancer-initiating cells that are multipotent and can recapitulate the characteristics of GBM including high motility, diversity of progeny, tendency to migrate along white matter tracts, and expression of immature antigenic phenotypes such as epidermal growth factor receptor and nestin (10). Cancer-initiating cells may express CD133 (11), although cancer-initiating cells that do not express CD133 have been identified (12–14), indicating that this is not a definitive marker for the identification of cancer-initiating cells. Furthermore, the expression of CD133 is heterogeneous within neurospheres and can alter with subsequent passage and cloning (15). Characteristics of cancer-initiating cells also include high levels of the antiapoptotic genes, the ability to form neurospheres, nonadherence, possession of marker characteristics for astrocytic, neuronal, and oligodendroglial lineages (16), and tumorigencity in vivo. The cancer-initiating cells are believed to confer the resistance to chemotherapy and radiation observed in GBM (17, 18). Because significant T-cell immune suppression is induced by the GBM and because glioblastoma-associated cancer-initiating cells are a therapeutically resistant population, the question arises as to the participation of cancer-initiating cells in inhibiting T-cell responses.

The signal transducer and activator of transcription 3 (STAT3) pathway is a potent regulator of anti-inflammatory responses through its suppression of macrophage activation (19, 20), reduction of the cellular cytotoxicity of natural killer cells and neutrophils, and reduction of the expression of MHC II, CD80, CD86, and IL-12 in dendritic cells rendering them unable to stimulate T cells and generate antitumor immunity (21). The ablation of STAT3 activity in only the immune cells results in marked antitumor effects in vivo, indicating that STAT3 expression within the immune cells is what restrains antitumor eradication (21). Recent evidence shows that GBM-associated immunosuppression is linked to the upregulation of STAT3 in tumor cells (22). Many growth factors and cytokines, including IL-6 and epidermal growth factor, activate Janus kinase 2, which subsequently activates STAT3 by phosphorylation of the tyrosine residue in the transactivation domain. Phosphorylated STAT3 (p-STAT3), which is overexpressed in most cancers including gliomas (23, 24), then translocates into the nucleus and induces a variety of transcriptional factors that propagate tumorigenesis (25) and upregulate tumor-mediated immunosuppressive factors (26). These factors include IL-10 (27, 28) that adversely influences Th1-mediated cytotoxic immune responses at multiple levels and is essential for Treg function (29, 30), vascular endothelial growth factor (31) that inhibits dendritic cell maturation and activation by inhibiting costimulatory molecule expression (32), PGE₂ (33) that induces the immune-suppressive Th17 cell (34), and TGF-β (35) that induces Tregs, inhibits T-cell proliferation, and downmodulates the IL-2 receptor (reviewed in ref. 36), to name just a few. These STAT3-regulated tumor-secreted factors then activate STAT3 in diverse immune cells including both innate immune cells and T cells (21). Because STAT3 target genes encode many factors that activate STAT3 in the immune cells, a feed-forward mechanism for constitutive activation of STAT3 in both the tumor cells and the immune cells within the tumor microenvironment is initiated. Cumulatively, these data indicate that the STAT3 pathway is a molecular hub of tumor-mediated immune suppression.

The inhibition of STAT3 activity in only the hematopoietic cells of tumor-bearing mice can induce potent multicomponent antitumor immune responses (21). We have previously found that inhibition of STAT3 with WP1066, which blocks the Janus kinase 2/STAT3 interaction and subsequent phosphorylation of STAT3 at tyrosine⁷⁰⁵ (p-STAT3; ref. 37), results in the upregulation of costimulatory molecules (CD80 and CD86) on human microglia, secretion of proinflammatory cytokines essential for T-effector responses, and activation and proliferation of T cells (22). Thus, STAT3 blockade is a potent approach for modulating multifactorial immunosuppression and eliciting antitumor immune responses. Cancer-initiating cells have been shown to have activated p-STAT3 that can be blocked with p-STAT3 inhibitors, resulting in diminished stem cell proliferation, neurosphere formation, and depletion of CD133-positive (CD133+) cells (38). Specifically, the STAT3 inhibitor WP1066 can induce apoptosis of human glioma cells both in vitro and in vivo (39), can reverse glioma-mediated immune suppression (22), is orally bioavailable, achieves excellent CNS penetration, exerts efficacy against established intracerebral tumors with minimal toxicity (40), and can inhibit Tregs (41). Based on the aforementioned properties (42) and the pending investigational new drug application of WP1066, we selected WP1066 and small interfering RNA (siRNA) for these studies to test the hypothesis that if cancer-initiating cells mediate T-cell immune suppression, then the p-STAT3 pathway would likely be a key mediator of this immune suppression that could be reversed by blockade of the STAT3 pathway.

Human normal astrocytes and glioma cell lines U-251 and U-87 were purchased from the American Type Culture Collection and cultured in RPMI 1640 (astrocytes), modified Eagle's medium (U-251) or modified Eagle's medium plus 0.1 mmol/L nonessential amino acids (U-87). To all media, 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin were added.

Tumor tissues from newly diagnosed GBM patients (n = 9) were obtained from surgery specimens and were graded pathologically according to the WHO classification system by a neuropathologist. Each patient provided written informed consent for tumor tissues and this study was conducted under protocol #LAB03-0687, which was approved by the institutional review board of The University of Texas M. D. Anderson Cancer Center.

GBM specimens were processed within 4 h after resection. They were washed and disassociated mechanically. After a single-cell suspension was prepared, erythrocytes were lysed using 1× RBC lysis buffer (eBioscience). Trypan blue staining confirmed >80% cell viability. Glioma-associated cancer-initiating cells were cultured in DMEM F-12 containing 20 ng/mL of epidermal growth factor, basic fibroblast growth factor (Sigma), and B27 (1:50; Invitrogen) as a neural stem cell–permissive medium (neurosphere medium) and passaged every 5 to 7 d. CD133 expression on glioma-associated cancer-initiating cells was confirmed before use.

Single-cell suspensions of glioma-associated cancer-initiating cells in serum-free medium at 2 × 10² cells per 5 μL were injected into the right frontal lobes of 58-wk-old nude mice using a stereotactic frame system (Kopf Instruments) as described previously (43). Mice were maintained in the M.D. Anderson Isolation Facility in accordance with Laboratory Animal Resources Commission standards and conducted according to an approved protocol, 08-06-11831.

Accutase-dissociated (Sigma) glioma-associated cancer-initiating cells were sorted using the CD133 cell isolation kit (Miltenyi Biotech), and >90% purity CD133+–sorted cells were seeded into 96-well plates at a theoretical density of one cell per well. After overnight culture, microscopic observation was used to identify wells that contained a single cell. These wells were monitored and the medium was changed every 5 to 7 d for 45 d before immune functional analysis.

Peripheral blood mononuclear cells (PBMC) were prepared from healthy donor blood (Gulf Coast Blood Center) and GBM patients' blood (the same patients whose glioma-associated cancer-initiating cells were isolated) by centrifugation on a Ficoll-Hypaque density gradient (Sigma-Aldrich). Aliquots of the isolated PBMCs were frozen and stored at −180°C until used. Before coculture experiments, frozen PBMCs were thawed at 37°C for 5 min and then washed with warm 10% FBS in RPMI 1640. CD3+ T cells were purified from PBMCs by negative selection using a Pan T Cell Isolation kit II (Miltenyi Biotech), according to the manufacturer's instructions.

Tissue culture grade monoclonal antibodies to CD3 (OKT3) and CD28 (28.6) were obtained from eBioscience. Anti-human IL-6 (1936) and anti-human TGF-β1 (27235) antibodies were obtained from R&D Systems. WP1066 was synthesized and supplied by Waldemar Priebe, and was stored as a 10 mmol/L stock in DMSO and diluted with PBS when used. WP1066 was used at doses that could be achieved in vivo (1–5 μmol/L; ref. 40). The cell surface was stained with phycoerythrin (PE), FITC, or allophycocyanin (APC)-conjugated antibodies against the following proteins: CD3, CD4, CD8, MHC I, MHC II, CD40, CD80, CD86, B7-H1 (BD Pharmingen), and CD133 (Miltenyi Biotech). To detect intracellular cytokines, PE-conjugated antibodies against IL-2 and IFN-γ (R&D Systems) were used. Intracellular STAT3 was assessed using PE-conjugated p-STAT3 (pY⁷⁰⁵; BD Pharmingen). Appropriate isotype controls were used for each antibody.

FITC-conjugated anti-CD4 (RPA-T4) and APC-conjugated anti-CD8 (RPA-T8) antibodies were used for cell surface staining. Subanalysis of the T-cell populations was based on the gated surface expression of CD4 and CD8. To detect forkhead box P3 (FoxP3) protein expression, the surface-stained cells were further subjected to intracellular staining with PE-conjugated monoclonal antibodies to human FoxP3 (clone PCH101, eBioscience) using staining buffers and conditions specified by the manufacturer. For intracellular cytokine staining, cells were stimulated for 6 h in the presence of 50 ng/mL phorbol myristate acetate, 500 ng/mL ionomycin (Sigma-Aldrich), and 2 μmol/L monensin (GolgiStop, BD Pharmingen). Then, the cells were incubated with FITC-conjugated anti-CD4 and APC-conjugated anti-CD8 (RPA-T8) antibodies for surface staining followed by intracellular staining using PE-conjugated anti-mouse IFN-γ (4S.B3) or PE-conjugated anti-mouse IL-2 (MQ1-17H12) antibodies and FIX/PERM buffers (BD Pharmingen) according to the manufacturer's instructions. Intracellular p-STAT3 intracellular staining was done as described previously (41). Flow cytometry acquisition was done with a FACSCaliber (Becton Dickinson) and data analysis was with FlowJo software (TreeStar).

Accutase-dissociated glioma-associated cancer-initiating cells were cultured in differentiation medium consisting of 10% FBS, 10 ng/mL retinoic acid, and 20 ng/mL platelet-derived growth factor-AA (both from Sigma-Aldrich; ref. 44). Confluent monolayer cells were detached every 5 to 7 d by trypsinization, and retinoic acid and platelet-derived growth factor-AA were replenished during the culture.

Differentiated glioma-associated cancer-initiating cells were cultured on eight-chamber slides (Nunc) at 5,000 per well. After 3 d, cells were fixed with 4% paraformaldehyde, permeabilized with 3% Triton X-100 in PBS, and then blocked with 5% horse serum. Primary antibodies were rabbit anti-GFAP (1:40; DAKO), mouse anti-galactosylceramidase (1:100; Chemicon), and mouse anti-microtubule associate protein 2 (MAP2; 1:50; Chemicon). After incubation for 90 min, the slides were washed with 5% horse serum. Secondary antibodies, goat anti-rabbit Alexa 546 (1:300; Invitrogen), and donkey anti-mouse Alexa 488 (1:300; Invitrogen) were added for 30 min. Slides were mounted using Vectashield Hard Set mounting medium with 4′,6-diamidino-2-phenylindole (Vector Laboratories).

Supernatants from the human glioma cell lines U-87 and U-251, and the glioma-associated cancer-initiating cells were measured for cytokine concentrations using ELISA kits per manufacturer's instructions (R&D Systems). These supernatants were collected after 5 d in culture and stored at −20°C. The supernatants were added in duplicate to appropriate precoated plates. The absorbance was measured at 450 nm with a microplate reader (Spectra Max 190; Molecular Devices), and chemokine concentrations were quantitated with SoftMax Pro software (Molecular Devices). The detection limits for chemokine C-C motif-2 (CCL-2) were 5 pg/mL, 16 pg/mL for TGF-β1, 5 pg/mL for IL-10, 1 pg/mL for IL-6, 10 pg/mL for PGE₂, 10 pg/mL for soluble Fas, and 10 pg/mL for Galectin-3.

Glioma-associated cancer-initiating cells were plated into 48-well plates (3 × 10⁴ cells/mL) containing 3 × 10⁵ PBMCs/mL in the presence of 1 μg/mL prebound anti-CD3/anti-CD28 antibodies or 2.5 μg/mL phytohemagglutinin (Sigma-Aldrich). Alternatively, conditioned media from the glioma-associated cancer-initiating cells were also added to the stimulated PBMCs. After 72 h, 100 μL of cells from each well were transferred to new 96-well plates with 10 μL of Cell Counting kit-8 (Dojindo Laboratories). After incubation for 4 h at 37°C, absorbance was measured at 450 nm with a microplate reader (Spectra Max 190). To detect FoxP3+ Tregs, CD4 surface staining and then FoxP3 intracellular staining were done on immune cells cultured for 96 h.

Healthy donor PBMCs were labeled with 2 μmol/L carboxyfluorescein diacetate succinimidyl ester (CFSE) for 5 min at room temperature in PBS with 0.1% bovine serum albumin, and then the reaction was quenched with RPMI 1640 with 10% FBS for 10 min at 37°C. CFSE-labeled PBMCs (1 × 10⁶/mL) and autologous T cells (1 × 10⁵/mL), which were cultured with conditioned media from glioma-associated cancer-initiating cells for 4 d, were plated into 96-well plates in the presence of 2 × 10⁶/mL allogeneic-irradiated PBMCs in RPMI 1640 with10% FBS in a total volume of 0.2 mL. After 72 h, the cells were harvested, and analysis of cell division was done by flow cytometry.

The T-cell apoptosis assay was done with the Annexin V/7AAD staining kit (BD Pharmingen). Healthy donor PBMCs were cultured with medium or glioma-associated cancer-initiating cell supernatants and then harvested by centrifugation at day 3 and 5. The cells were stained with APC-conjugated anti-CD3 antibodies and then washed twice with cold PBS and resuspended in 1× binding buffer (BD Pharmingen) at a concentration of 1 × 10⁶ cells/mL. Next, PE-conjugated Annexin V and 7-AAD were added; the cells were incubated for 20 min at 25°C in the dark; and CD3+ T-cell apoptosis was analyzed by flow cytometry within 1 h.

To knock down STAT3 gene expression in glioma-associated cancer-initiating cells, STAT3 siRNA was transfected into two of our established glioma-associated cancer-initiating cell lines as described (Santa Cruz Biotech). Briefly, 2 × 10⁵ glioma-associated cancer-initiating cells per well were seeded in 2 mL antibiotic-free medium in six-well plates and incubated for 8 h. The siRNA duplex solution (1 μg STAT3 siRNA or control siRNA) in 100 μL siRNA transfection medium were prepared and gently mixed with diluted siRNA transfection reagent and incubated for 45 min at room temperature. The mixture was then overlaid onto the cells washed by transfection medium. The cells were incubated for 5 h at 37°C; then, 1 mL of neurosphere medium was added and the cells were cultured for an additional 72 h before conducting the immune functional assays.

All values were calculated as means and 95% confidence intervals from at least three independent experiments. The Student's t test was used to test for differences in the means between two groups. P values of <0.05 were considered to be statistically significant. All statistical analyses were done using the Statistical Package for the Social Sciences v.12.0.0 (SPSS). Error bars represent SD.

From newly diagnosed GBM patients (n = 9) at the time of surgery, we isolated cancer-initiating cells and the patients' autologous T cells. The cancer-initiating cells from the patients expressed CD133, formed neurospheres (Fig. 1A) in serum-free medium containing epidermal growth factor and basic fibroblast growth factor after 5 to 10 days of culture, and these CD133+ cells express CD34 but not CD45, indicating that they are of endothelial origin (Fig. 1B; ref. 45). The established cancer-initiating cells were capable of differentiating into glial fibrillary acidic protein (GFAP+) astrocyte-like cells, neuron-like cells that were immunoreactive for mouse anti-microtubule associate protein 2, and galactosylceramidase-immunoreactive oligodendrocyte-like cells (Fig. 1C). When the cancer-initiating cells were injected into the right frontal lobes of 5- to 8-week-old nude mice, the mice developed tumors that were highly infiltrative along white matter tracts—a characteristic of human GBM (Fig. 1D). To further characterize the cancer-initiating cells, CD133+ cancer-initiating cells were sorted from the neurospheres and diluted for single colony formation. Over 80% of seeded single cells grew out, and 10 clones from each neurosphere were selected at random and expanded for further immunologic characterization.

To characterize their immunologic phenotype, the cancer-initiating cells (n = 5) were assessed for their expression of MHC I, MHC II, CD40, CD80, CD86, and B7-H1 by flow cytometry. The cancer-initiating cells expressed high levels of MHC I (mean, 99.3%; range 98.5–99.8%) and low levels of CD86 (mean, 6.7%; range, 5.9–7.9%) and CD40 (mean, 5.8%; range, 0.7–15.8%), but not MHC II (mean, 2.4%; range, 1.6–3.2%) or CD80 (mean, 0.6%; range, 0.2–0.6%; a representative example is shown in Fig. 2A), indicating that cancer-initiating cells lack the capacity for antigen presentation necessary to stimulate T-cell activation or proliferation. Furthermore, the inhibitory costimulatory molecule B7-H1 (mean, 31.2%; range 28.5–34.9%) was expressed, indicating that direct contact between T cells and cancer-initiating cells would be inhibitory on immune cells.

To evaluate what immunosuppressive cytokines the cancer-initiating cells were elaborating, the cancer-initiating cells (n = 4) and established glioma cell lines were assayed for immunosuppressive cytokines such as TGF-β1, IL-6, IL-10, PGE₂, soluble Fas, and vascular endothelial growth factor by ELISA. The cancer-initiating cells did not produce any appreciable IL-6, IL-10, or soluble Fas, but did produce TGF-β1 (38.5–118 pg/mL) and the Treg chemokine attractant CCL-2 (12.8–1134 pg/mL; Table 1).

To determine if the cancer-initiating cells could inhibit the proliferation and elaboration of proinflammatory responses of immune cells, PBMCs from healthy donors were activated with anti-CD3/CD28 or phytohemagglutinin in the presence of conditioned medium obtained from 3-day cultures of cancer-initiating cells, and T-cell proliferation was assessed by flow cytometry. The media from all of the CD133+ clones (n = 20, generated from two GBM specimens, and 10 clones from each) potently inhibited T-cell proliferation by 91 ± 12% (P = 0.0005). No inhibition of T-cell proliferation was detected when the conditioned medium was obtained from either normal human astrocytes or the U-87 cell line. To ascertain if the supernatants could also inhibit the elaboration of the proinflammatory cytokines IL-2 and IFN-γ from the CD4+ T-cell helper and the CD8+ T-cell effector subset, the cancer-initiating cell supernatants were coincubated with the healthy donors' PBMCs in the presence of antiCD3/CD28 stimulation, and the percentages of CD4+ and CD8+ T cells producing IL-2 and IFN-γ were determined by intracellular staining via flow cytometry. The production of both IFN-γ and IL-2 by the CD4+ and CD8+ T-cell subsets was suppressed by the cancer-initiating cell supernatants (Table 2). These data show that cancer-initiating cells suppress T-cell proliferative and proinflammatory responses.

Because the cancer-initiating cells were producing TGF-β, we next determined if these cells could induce Tregs. Incubation with supernatants from the cancer-initiating cells (18 of 20) markedly expanded the number of CD4+FoxP3+ Tregs in healthy donor PBMCs by 128 ± 51% (P = 0.0007; representative example in Fig. 2B). These FoxP3+ Tregs were functionally suppressive in autologous T-cell proliferation assays (Fig. 2C). All of the cancer-initiating supernatants (n = 20) were able to increase immune cell apoptosis by 144 ± 29% (P = 0.0001) in healthy donor PBMCs. Furthermore, when the GBM patients' PBMCs were coincubated with the respective patients' cancer-initiating cells, as predicted from the phenotypic expression of B7-H1, both preapoptosis and apoptosis were induced in the immune cells (representative example in Fig. 2D). Conditioned media from normal human astrocytes and the U-87 glioma cell line did not induce T-cell apoptosis. Activated immune cells also underwent apoptosis when cocultured with conditioned medium from cancer-initiating cells, indicating that activation did not protect immune cells from the apoptosis induced by conditioned medium from cancer-initiating cells. This indicates that cancer-initiating cells can mediate immunosuppression by apoptotic elimination of immune cells, regardless of their activation state, likely by both secretion of product(s) and direct cell-to-cell contact.

The expression of p-STAT3 by tumor cells triggers a cascade of transcriptional factors that have been shown to activate p-STAT3 in immune cells (26). In addition, cancer-initiating cells have been shown to express p-STAT3 (38). The p-STAT3 expression of cancer-initiating cells can be inhibited with the STAT3 siRNA (Fig. 3A), and this treatment did not affect cell viability based on trypan blue exclusion. The supernatants from cancer-initiating cells (n = 3) were capable of increasing p-STAT3 expression in immune cells by 64.7 ± 12.5% (P = 0.006; representative in Fig. 3B). When the cancer-initiating cells were treated with the STAT3 siRNA and then healthy donor PBMCs (n = 3) were subsequently exposed to conditioned media from these glioma-associated cancer-initiating cells, the induction of p-STAT3 was significantly diminished in the immune cells (Fig. 3B). Similar data were obtained with the small molecular inhibitor of the p-STAT3 pathway WP1066.

To determine if p-STAT3 blockade can change the immunosuppressive functions of the cancer-initiating cells, the cancer-initiating cells were treated with the STAT3 siRNA and phenotypically and functionally characterized. Treatment did not alter the expression of MHC II, CD40, CD80, CD86, or B7-H1 (data not shown). In contrast to the marked inhibition of T-cell proliferation with the supernatant from the cancer-initiating cells, the supernatants from siRNA-treated cancer-initiating cells did not inhibit T-cell proliferation (Fig. 4A); there was restoration of the number of T cells secreting IL-2 and IFN-γ; T-cell apoptosis was inhibited (Fig. 4B); and there was a reduction in glioma-associated cancer-initiating cells–induced FoxP3+ Tregs (Fig. 4C). Identical data were obtained with the small molecular inhibitor of the p-STAT3 pathway WP1066 (Fig. 4D–F). The treatment of cancer-initiating cells (n = 3) with the STAT3 siRNA decreased the production of Galectin-3 from 1,967 ± 1,151 to 920 ± 423 pg/mL (P < 0.05).

The immunologic properties of human cancer-initiating cells have not been defined previously, and to our knowledge, this is the first study to show that these cells mediate many of the key features of immunosuppression and suggests a possible mechanism for resistance to immunotherapy. To investigate the immune properties of glioma-associated cancer-initiating cells, we used two different approaches. In the first, the supernatants from glioma-associated cancer-initiating cells were used in immunologic assays with T cells from healthy donors to determine the effects of glioma-associated cancer-initiating cells in the absence of pre-existing T-cell immunosuppression while avoiding allogeneic responses that could confound the interpretation of the data. In the second approach, using GBM patients' T cells and the respective patients' glioma-associated cancer-initiating cells, allogeneic interactions would not confound the data, allowing for analysis of direct cell-to-cell contact; however, pre-existing immune suppression in the patient T cells might dampen the extent of immunosuppression exerted by the glioma-associated cancer-initiating cells. Regardless of the experimental approaches, the data showed that the glioma-associated cancer-initiating cells inhibit T cell–mediated responses.

More specifically, although the glioma-associated cancer-initiating cells expressed MHC I, they lacked MHC II, CD40, and CD80 expression, which would be anticipated to induce T-cell anergy (46), and this was confirmed in our functional assays of T-cell proliferation. The glioma-associated cancer-initiating cells expressed the costimulatory inhibitory molecule B7-H1, which has previously been shown to be a key factor mediating immune resistance in gliomas (47) and can induce T-cell apoptosis (48). Thus, it was not unexpected to find in the direct cell-to-cell contact experiments that the glioma-associated cancer-initiating cells induced T-cell apoptosis in the scenario of B7-H1 expression. Additionally, it was not entirely surprising to see that cancer-initiating cells could induce Tregs that were functionally active and have been shown to contribute to the immune suppression in malignant glioma patients (49–51) because the cancer-initiating cells elaborated TGF-β (10–100 pg/mL) at levels sufficient to induce Tregs (52). Interestingly, the cancer-initiating cells also produced PGE₂, which has been shown to regulate Th17 cell function (34). The Th17 immune cell population has recently been shown to promote tumor growth through the IL-6-STAT3 pathway (53). Likely, additional STAT3-mediated cancer-initiating mechanisms of immune suppression will be identified possibly with cytokine microarrays. Although the glioma cell lines U-87 and U-251 also produce TGF-β1, they failed to show significant inhibition of T-cell proliferation that is likely secondary to the elaborated IL-6 being produced, which is a potent driver for T-cell proliferation (54), indicating a complex interplay among the various secreted components. Cumulatively, these data indicate that in addition to the previously identified key role of glioma-associated cancer-initiating cells in mediating radiation resistance (17) and chemotherapy resistance (11, 55, 56), glioma-associated cancer-initiating cells also contribute to T-cell immune suppression by multiple mechanisms.

In this report, we also show that the supernatants from the glioma-associated cancer-initiating cells could increase the number of immune cells expressing p-STAT3, likely by one or more of the previously characterized STAT3-transcriptionally controlled tumor-secreted factors. The treatment of the STAT3 expressing glioma-associated cancer-initiating cells with STAT3 siRNA or WP1066 diminished the percentage of immune cells expressing p-STAT3 that were exposed to the supernatant from the glioma-associated cancer-initiating cells. Although treatment of glioma-associated cancer-initiating cells with STAT3 siRNA or WP1066 did not alter the immunologic phenotype of the glioma-associated cancer-initiating cells, as reflected by the levels of expression of MHC or costimulatory molecules, the treatment of the glioma-associated cancer-initiating cells with either STAT3 siRNA or WP1066 did partially restore T-cell proliferation and effector function secondary to decreased T-cell apoptosis and Tregs. In the case of the PBMCs exposed to the supernatants from the cancer-initiating cells treated with the STAT3 inhibitors, the decrease in Tregs could possibly be secondary to residual STAT3 siRNA or WP1066 in the medium that blocks FoxP3 expression in human CD4+CD25+ Tregs (57). Or alternatively, the blockade of the STAT3 pathway in the cancer-initiating cells resulted in the downmodulation of secreted factors that induce Tregs. In the case of the PBMCs exposed to the supernatants from the cancer-initiating cells treated with the STAT3 inhibitors, the decrease in T-cell apoptosis is likely secondary to a decrease in Galectin-3. Soluble Galectin-3 has been shown to induce T-cell apoptosis (58), is expressed in glioma cell lines but not normal astrocytes or oligodendrocytes (59), and has been shown to enhance glioma proliferation and migration (60). Upon treatment with the STAT3 inhibitors, we found a decrease in the amount of Galectin-3 production that was responsible for the T-cell apoptosis. However, because we observed only partial blockade of T-cell apoptosis with the STAT-3 inhibitors, thus accounting for the incomplete restoration of T-cell proliferation and effector function, a STAT-3–independent pathway such as B7-H1 expression is likely also operational in the cancer-initiating, cell-mediated T-cell apoptosis.

Although we have shown that blockade of the STAT3 pathway with siRNA and the small-molecule inhibitor WP1066 could reverse cancer-initiating, cell-mediated immune suppression, other molecules such as JSI-124 (61) and NSC 74859 (62), among many others, targeting the STAT3 pathway could also potentially exert the same effects. A variety of molecular inhibitors of STAT3 have been devised. These molecular inhibitors interfere with the signaling of STAT3 by blocking the ligand-receptor interaction and activation sites of STAT3, dimerization, nuclear translocation, DNA binding, and gene transcription. Conceivably, the inhibitors of the STAT3 pathway may be able to overcome cancer-initiating, cell-mediated chemoradiation and radiation therapeutic resistance in addition to immune suppression, but this awaits more detailed study. Further investigations will be necessary to ascertain how to optimize the STAT3 inhibitors in combination with other immune therapeutics. Finally, because our data indicate that the STAT3 pathway is a significant molecular pathway mediating cancer-initiating cell-mediated immune suppression, newer murine model systems are under development. These murine model systems are immune competent and have constitutive overactivation of the STAT3 pathway under the GFAP promoter. These models may ultimately be more applicable to glioma tumorigenesis and may more accurately recapitulate heterogeneous human gliomas as opposed to clonotypic xenografts. These murine models may also provide an enriched population of murine glioma cancer-initiating cells in which agents that block the STAT3 pathway could be tested.

No potential conflicts of interest were disclosed.

We thank Lamonne Crutcher for the assistance in obtaining tissue specimens and Melissa Burkett and Adelina “Keats” Fuentes for the editorial assistance.

Grant Support: The Anthony Bullock III Foundation (A.B. Heimberger), the Dr. Marnie Rose Foundation (A.B. Heimberger), the University of Texas M.D. Anderson Cancer Center (A.B. Heimberger), and the NIH grant CA120813-01 (A.B. Heimberger).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.